Indonesia Hypersomnia Therapeutics Market Analysis

Indonesia Hypersomnia Therapeutics Market Executive Summary

The Indonesia Hypersomnia Therapeutics Market is at around $84.18 Mn in 2023 and is projected to reach $101.44 Mn in 2030, exhibiting a CAGR of 2.70% during the forecast period.

Hypersomnia is a group of neurological disorders characterized by excessive daytime sleepiness, despite getting enough sleep at night. This can significantly impair daily functioning and reduce quality of life. While the exact causes are still being researched, hypersomnia can be linked to underlying medical conditions, neurological disorders, or disruptions in sleep regulation mechanisms. People with hypersomnia often experience symptoms such as not feeling refreshed upon waking, feeling groggy and slow for extended periods after waking, and an excessive need for sleep despite sleeping for long periods. Chronic headaches, loss of appetite, excessive sweating, and depression have also been reported. Treatment for hypersomnia focuses on managing daytime sleepiness. This can involve adopting healthy lifestyle practices like eating well and exercising regularly. Medications like stimulants can also be prescribed to promote wakefulness. In some cases, cognitive behavioral therapy for insomnia (CBT-I) can help address underlying sleep habits that contribute to hypersomnia.

Indonesia faces a significant public health burden with an estimated prevalence of 29% of the population. The market therefore is driven by substantial factors like the increasing awareness about hypersomnia disorders, rising aging population, and increasing healthcare expenditure. However, high costs of treatment, limited accessibility to specialized healthcare services, and potential side effects restrict market growth.

The leading pharmaceutical companies include Kalbe Farma and Dexca Medica. Takeda Pharmaceuticals, Pfizer, and Merck Tbk are also significant contributors to the hypersomnia therapeutics landscape, with continuous research and development activities.

Market Dynamics

Market Growth Drivers

Increasing Awareness about Hypersomnia Disorders: Increased awareness can lead to a larger pool of potential patients for hypersomnia medications. This can benefit patients who can finally get treatment and pharmaceutical companies developing these medications. It can help people recognize the symptoms of hypersomnia and encourage them to seek medical attention.

Expanding Geriatric Population: Hypersomnia may be more common in older adults due to changes in sleep structure and health conditions. With approximately 7% of the elderly population, the prevalence of hypersomnia is predicted to increase, increasing the need for effective treatment options that meet the unique needs of older adults.

Increasing Healthcare Expenditure: A rise in Indonesia's healthcare spending could be a double win for people with hypersomnia. Firstly, more people might be covered by health insurance, making hypersomnia medications more affordable. Secondly, increased spending could lead to better stocking of these medications in hospitals and clinics, allowing easier access to the right treatment.

Market Restraints

High Cost of Treatment: The high cost of treatment, including the cost of medications and healthcare services, can be a significant barrier for many patients. This can lead to delayed or inadequate treatment, which negatively impacts market growth.

Limited Accessibility to Specialized Healthcare Services: Access to specialized sleep disorder clinics, neurologists, and sleep medicine specialists is restricted in certain areas, particularly in rural. As a result, individuals with hypersomnia disorders face barriers to timely diagnosis, appropriate treatment, and ongoing management, leading to underdiagnosis and undertreatment of the condition.

Potential Side Effects:  While the medicines help manage excessive sleepiness, they often come with side effects that can be unpleasant. This discourages some people from seeking treatment in the first place, or they might stop taking the medication altogether because of the side effects. This situation is unfortunate because it not only reduces the quality of life for people with hypersomnia but also hinders the growth of the hypersomnia medication market in Indonesia for pharmaceutical companies.

Regulatory Landscape and Reimbursement Scenario

The National Agency for Food and Drug Control (BPOM) is the primary authority overseeing drug registration, marketing, and distribution in Indonesia. BPOM is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products, including those used to treat hypersomnia.

JKN-KIS is a single-payer universal health insurance scheme, administered by the Ministry of Health (MoH) and is funded through a combination of government subsidies, and social health insurance premiums. It aims to achieve universal health coverage by providing basic medical care in public facilities free for all citizens. The MoH maintains a list of reimbursed medicines, known as the National Formulary (NF). Only medicines listed in the NF are eligible for reimbursement.

The applicant submits a pre-registration application, to obtain a license for a pharmaceutical product. After the pre-registration is deemed complete, the application enters the evaluation stage by the Indonesian Food and Drug Administration (BPOM). It reviews the submitted documents for completeness and accuracy. If satisfied, BPOM issues a marketing authorization for the product which is valid for 5 years.

Competitive Landscape

Key Players

Here are some of the major key players in the Indonesia Hypersomnia Therapeutics Market:

• Kalbe Farma
• Dexca Medica
• Kimia Farma
• Pfizer
• Merck Tbk
• Teva Pharmaceuticals
• Indofarma
• Takeda Pharmaceuticals
• GlaxoSmithKline
• Pyridam Farma